

Supplementary Table 1. Descriptive statistics including sociodemographic characteristics, family history and lifestyle associated with hair and scalp, and medication status of PD patients

Total (<i>n</i> = 495)	
Sociodemographic characteristics	
Age	
≥ 65 yr	344 (69.5)
Median, min/max	69, 33–90
Sex, male	225 (45.5)
Smoking status	
None	350 (70.7)
Ex-smoker	119 (24.0)
Current smoker	26 (5.3)
Alcohol consumption	
Yes	149 (30.1)
BMI	
≥ 23, kg/m ²	262 (52.9)
Clinical characteristics	
Hypertension	
Yes	195 (39.4)
Diabetes	
Yes	91 (18.4)
Dyslipidemia	
Yes	53 (10.7)
End-stage renal disease	
Yes	5 (1.0)
Cardiac disease	
Yes	53 (10.7)
Coronary artery disease	40 (8.1)
Others	13 (2.6)
Stroke	
Yes	6 (1.2)
Thyroid disease	
Yes	29 (5.9)
Autoimmune disorder (Lupus, Schogren)	
Yes	3 (0.6)
Cancer (except thyroid cancer)	
Yes	37 (7.5)
Psychiatric disease	
Yes	21 (4.2)
Dermatologic diagnosis	
Yes	35 (7.1)
PD diagnosis to hair examination duration*, month	54 (1–283)
Initial PD symptoms to hair examination duration*, month	68 (3–295)
History associated with hair and scalp	
Location of hair loss	
No complaints	357 (177:180)
Number (M:F)	
Diffuse	68 (23:45)
Parietal	24 (10:14)
Frontotemporal	43 (13:30)
Occipital	3 (2:1)
Family history of alopecia	
None	332 (67.1)
Paternal	60 (12.1)
Maternal	14 (2.8)
Sister/brother	52 (10.5)
More than 2	37 (7.5)
Treatment for hair loss	
Nothing	374 (75.6)
Hair products	102 (20.6)
Drug (PO, Topical)	1 (0.2)
Extra (e.g., massage, diet)	3 (0.6)
More than 2	15 (3.0)
Perming count (count/year)*	0 (0–12)
Dyeing count (count/year)*	2.5 (0–72)
Use of hair dryer (count/week)*	0 (0–7)
Ponytail hairstyle	
Yes	26 (5.3)
Sleep time (hr)*	6.5 (1–15)
Medication	
Dopaminergic medication	
Levodopa	419 (84.6)
Dopamine agonist	242 (48.9)
Pramipexole	209 (42.2)
Ropinirole	32 (6.5)
Bromocriptine	1 (0.2)
COMT inhibitor	41 (8.3)
Amantadine	194 (39.2)
MAO-B inhibitor	188 (38.0)
Anticholinergics	60 (12.1)
Type of dopaminergic medication	
Levodopa only	241 (48.7)
Dopamine agonist only	64 (12.9)
Both levodopa and dopamine agonist	178 (36.0)
Neither levodopa nor dopamine agonist	12 (2.4)
Anti-dementia medication	
Cholinesterase inhibitors	45 (9.1)
Memantine	8 (1.6)
Other drugs	
Beta blocker	26 (5.2)
Quetiapine	45 (9.1)
Selective serotonin reuptake inhibitors	33 (6.7)
Polypharmacy	
Non-polypharmacy	313 (63.2)
Polypharmacy (≥ 5 drugs)	173 (34.9)
Excessive polypharmacy (≥ 10 drugs)	9 (1.8)

Values are presented as *n* (%) unless otherwise indicated.
*median (range).
PD, Parkinson's disease; BMI, body mass index; COMT, catechol-O-methyltransferase; MAO-B, monoamine oxidase-B; M, male; F, female; PO, per oral.